Download PDF
Geburtshilfe Frauenheilkd 2000; 60(1): 41-58
DOI: 10.1055/s-2000-9764
ORIGINALARBEIT

Georg Thieme Verlag Stuttgart · New York

2nd-line-Chemotherapie nach Platin- oder Platin-Paclitaxel-haltiger Primärtherapie beim Ovarialkarzinom: eine systematische Übersicht der publizierten Daten bis 1998

Second-line Chemotherapie after Platinum or Platinum and Paclitaxel-based Chemotherapy for Ovarian Cancer: A Systematic ReviewA. du Bois1 , H. J. Lück2 , T. Bauknecht3
  • 1 Klinik für Gynäkologie und gynäkologische Onkologie, Dr. Horst-Schmidt-Kliniken, Wiesbaden
  • 2 Frauenklinik im Oststadtkrankenhaus, Medizinische Hochschule Hannover
  • 3 Universitäts-Frauenklinik Bonn
  • 4 Universitäts-Frauenklinik Kiel
  • 5 Frauenklinik, ev. Krankenhaus Düsseldorf
Further Information

Publication History

Publication Date:
31 December 2000 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Trotz der in den letzten Jahrzehnten erreichten Fortschritte in der Primärbehandlung des fortgeschrittenen Ovarialkarzinoms erleidet die Mehrzahl der Patientinnen ein Rezidiv der Erkrankung. Die Entwicklung effektiver Rezidivtherapien ist klinisch relevant.

Diese Übersichtsarbeit re-analysiert die bis inklusive 1998 publizierten Daten zur systemischen Chemotherapie (366 Studien mit 13 584 Patientinnen). Hierbei werden die Patientinnenkollektive je nach der Art der Vortherapie (mit oder ohne Platin bzw. Paclitaxel) und dem Ansprechen auf die Vortherapie getrennt analysiert. Bei Letzterem werden Patientinnen mit platinsensiblem Ovarialkarzinom (d. h. Ansprechen auf eine platinhaltige Primärtherapie und Intervall bis zum Auftreten eines Rezidivs von mehr als 6 Monaten) und Patientinnen mit einem platinrefraktären Ovarialkarzinom (d. h. kein Ansprechen auf eine platinhaltige Primärtherapie oder Rezidiv innerhalb von 6 Monaten nach Abschluß der Primärtherapie) getrennt analysiert.

Beim platinsensiblen Ovarialkarzinom werden die besten Ergebnisse mit einer platinhaltigen Re-Induktionstherapie berichtet. Beim platinrefraktären Ovarialkarzinom unterscheiden sich die Ergebnisse verschiedener Chemotherapien nur unwesentlich, eine erneute Platintherapie erscheint wenig sinnvoll. Die Datenlage zu einer 2nd-line-Therapie nach Platin und Paclitaxel, dem aktuellen Standard in der Primärbehandlung ist ungenügend. Lediglich für Topotecan wurde bisher eine (begrenzte) Aktivität in ausreichend großen Studien bewiesen. Leider liegen nur unzureichende Daten aus prospektiv randomisierten Studien vor. Die bisher ungenügenden Therapieergebnisse und der offensichtliche Mangel an validen Daten sollte dazu führen, die 2nd-line-Therapien systematischer im Rahmen kooperativer klinischer Studien zu untersuchen. Die hier vorliegende retrospektive Analyse kann sowohl Hinweise für die Planung zukünftiger Studien geben, als auch helfen, Therapieentscheidung auf dem Boden der zur Verfügung stehenden Daten zu treffen.

Abstract

Purpose: Despite progress in the primary treatment of advanced ovarian cancer, most patients will still develop recurrent disease. We reviewed published studies on systemic second-line chemotherapy for patients with recurrent ovarian cancer.

Material and Methods: We systematically reviewed 366 studies including 13 584 patients published until 1998. Patients were divided into subgroups according to prior treatment (with or without platinum or paclitaxel) and response to prior treatment. Platinum-sensitive disease was defined as responce to platinum and progression-free survival of at least 6 months. Platinum-resistant disease was defined as no responce to platinum or a progression-free interval of less than 6 months after completion of primary treatment.

Results: Patients with platinum-sensitive disease did best after platinum-based reinduction therapy. For platinum-resistant disease there were no differences in response rates among the various published regimens; renewed platinum-based treatment was not effective. There are few data on second-line treatment for patients who have received platinum and paclitaxel. Only topotecan has been shown to have limited activity in adequately large studies. Few data are based on randomized trials.

Conclusions: Disappointing clinical results and a lack of valid data indicate a need for randomized clinical trials. Our data provide a basis for clinicians treating patients with recurrent ovarian cancer and suggest approaches for designing prospective trials.

Literatur

  • 1 McGuire W P, Hoskins W J, Brady M F. et al . Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.  J Engl J Med. 1996;  334 1-6
    CrossrefPubMedGoogle Scholar
  • 2 Stuart G, Bertelsen K, Mangioni C. et al . Updated analysis shows highly significant improved overall survival (OS) for cisplatin-paclitaxel as first-line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NOCOVA, NICIC-CTG and Scottish intergroup trial.  Proc Am Soc Clin Oncol. 1998;  17 1394
    PubMedGoogle Scholar
  • 3 Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.  J Clin Oncol. 1992;  10 513-514
    PubMedGoogle Scholar
  • 4 du Bois A, Lück H J, Meerpohl H G. Rezidiv- und 2nd-line Therapien beim Ovarialkarzinom: eine Übersicht konventioneller systemischer Therapiemodalitäten.  Zentrbl Gynäkol. 1997;  119 299-323
    PubMedGoogle Scholar
  • 5 Kavanagh J J, Tresukosol D, Edwards C. et al . Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer.  J Clin Oncol. 1995;  13 1584-1588
    PubMedGoogle Scholar
  • 6 Ozols R F, Ostchega Y, Curt C, Young R C. High-dose carboplatin in refractory ovarian cancer patients.  J Clin Oncol. 1987;  5 197-201
    PubMedGoogle Scholar
  • 7 Colombo N, Speyer J L, Green M. et al . Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients.  Cancer Chemother Pharmacol. 1989;  23 323-328
    CrossrefPubMedGoogle Scholar
  • 8 Williams L L, Fudge M, Burnett L S, Jones H W. Salvage carboplatin therapy for advanced ovarian cancer after first-line treatment with cisplatin.  Am J Clin Oncol. 1992;  15 331-336
    PubMedGoogle Scholar
  • 9 Eisenhauer E A, Swenerton K D, Sturgeon F G, Fine S, O'Reilly S E. Phase II study of carboplatin in patients with ovarian carcinoma: a National Cancer Institute of Canada Trials Group study.  Cancer Treat Rep. 1986;  70 1195-1198
    PubMedGoogle Scholar
  • 10 Gore M E, Fryatt I, Wiltshaw E, Dawson T, Robinson B A, Calvert A H. Cisplatin/carboplatin cross-resistance in ovarian cancer.  Br J Cancer. 1989;  60 767-769
    CrossrefPubMedGoogle Scholar
  • 11 Repetto L, Chiara S, Mammoliti S. et al . Crossover study with cisplatin or carboplatin in advanced ovarian cancer.  Gynecol Oncol. 1990;  39 146-149
    CrossrefPubMedGoogle Scholar
  • 12 Piver M S, Barlow J J, Lele S B, Malfetano J H, McPhee M E. Cis-diamminedichloroplatinum (II): second-line induction chemotherapy in advanced ovarian adenocarcinoma.  J Surg Oncol. 1983;  24 329-331
    PubMedGoogle Scholar
  • 13 Scotto V, Sbiroli C. Weekly cis-platin as third line chemotherapy in advanced ovarian carcinoma. Phase II study.  Eur J Gynaec Oncol. 1991;  12 51-53
    PubMedGoogle Scholar
  • 14 Chambers S K, Davis C A, Schwartz P E, Kohorn E I, Chambers J T. Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study.  Clin Cancer Res. 1996;  2 1693-1697
    PubMedGoogle Scholar
  • 15 Kjorstad K, Harris A, Bertelsen K. et al . A multicenter phase II study of carboplatin in advanced ovarian carcinoma: final report.  Ann Oncol. 1992;  3 217-222
    PubMedGoogle Scholar
  • 16 Pohl J, Meerpohl H G, Pfleiderer A. Phase II trial of carboplatin in advanced ovarian cancer.  Cancer Res Clin Oncol. 1988;  114 S53
    PubMedGoogle Scholar
  • 17 Hoskins P J, O'Reilly S E, Swenerton K D. The „failure free interval” defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing.  Int J Gynecol Cancer. 1991;  1 205-208
    PubMedGoogle Scholar
  • 18 Calvert A H, Harland S J, Newell D R. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.  Cancer Chemother Pharmacol. 1982;  9 140-147
    CrossrefPubMedGoogle Scholar
  • 19 Manetto A, Blessing J A, Hurteau J A. Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the Gynecologic Oncology Group.  Gynecol Oncol. 1998;  68 45-46
    CrossrefPubMedGoogle Scholar
  • 20 Chambers S K, Davis C A, Chambers J T, Schwartz P E, Lorber M T, Handschumacher R E. Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients.  Clin Cancer Res. 1996;  2 1699-1704
    PubMedGoogle Scholar
  • 21 Kavanagh J J, Edwards C L, Freedman R S. et al . A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer.  Gynecol Oncol. 1995;  58 106-109
    CrossrefPubMedGoogle Scholar
  • 22 Gietema J A, Veldhuis G J, Guchelaar H J. et al . Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.  Br J Cancer. 1995;  71 1302-1307
    PubMedGoogle Scholar
  • 23 Markman M, De Marco L C, Birkhofer M. et al . Phase II trial of zeniplatin (CL-286 588), a new platinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapy.  J Cancer Res Clin Oncol. 1993;  119 234-236
    CrossrefPubMedGoogle Scholar
  • 24 Sessa C, Vermorken J, Renard J et al. Phase II study of iproplatin in advanced ovarian carcinoma.  J Clin Oncol. 1988;  6 98-105
    PubMedGoogle Scholar
  • 25 Weiss G, Green S, Alberts D S. et al . Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study.  Eur J Cancer. 1991;  27 135-138
    PubMedGoogle Scholar
  • 26 Roberts J A, Kudelka A P, Spriggs D R. et al . A phase 2 study of cisplatin analog CI-973 in the treatment of patients with refractory, advanced ovarian cancer.  Int J Gynecol Cancer. 1996;  6 257-260
    CrossrefPubMedGoogle Scholar
  • 27 Chollet P, Bensmaine M A, Brienza S. et al . Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer.  Ann Oncol. 1996;  7 1065-1070
    PubMedGoogle Scholar
  • 28 Dieras V, Bounnoux P, Petit T. et al . Oxaliplatin (L-OHP) phase II study in platinum (PT) pretreated advanced ovarian cancer (AOC): preliminary results.  Proc Am Soc Clin Oncol. 1998;  17 364A
    PubMedGoogle Scholar
  • 29 Soulie P, Bensmaine A, Garrino C. et al . Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.  Eur J Cancer. 1997;  33 1400-1406
    CrossrefPubMedGoogle Scholar
  • 30 Piccart-Gebhart M, Green J, Lacave A. et al . Oxaliplatin (L-OHP) phase II study platinum (Pt) pretreated advanced ovarian cancer (AOC): preliminary results.  Proc Am Soc Clin Oncol. 1998;  17 1405
    PubMedGoogle Scholar
  • 31 Kavanagh J J, Kudelka A P, Gonzales de Leon C. et al . Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum.  Clin Cancer Res. 1996;  2 837-842
    PubMedGoogle Scholar
  • 32 Aapro M, Pujade-Lauraine E, Lhomme C. et al . EORTC Clinical Screening Group phase II study of taxotere in ovarian cancer.  Ann Oncol. 1994;  5 202
    PubMedGoogle Scholar
  • 33 Francis P, Schneider J, Hann L. et al . Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.  J Clin Oncol. 1994;  12 2301-2308
    PubMedGoogle Scholar
  • 34 Kaye S B, Piccart M, Aapro M, Francis P, Kavanagh J. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer - an updated overview.  Eur J Cancer. 1997;  33 2167-2170
    CrossrefPubMedGoogle Scholar
  • 35 Seewaldt V L, Greer B E, Cain J M. et al . Paclitaxel (taxol) treatment for refractory ovarian cancer: phase II clinical trial.  Am J Obstet Gynecol. 1994;  170 1666-1671
    PubMedGoogle Scholar
  • 36 Trimple E L, Adams J D, Vena D. et al . Paclitaxel for platinum-refractory ovarian cancer: results from the first 1000 patients registered to National Cancer Institute Treatment Referral Center 9103.  J Clin Oncol. 1993;  11 2405-2410
    PubMedGoogle Scholar
  • 37 Eisenhauer E A, ten Bokkel Huinink W W, Swenerton K D. et al . European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.  J Clin Oncol. 1994;  12 2654-2666
    PubMedGoogle Scholar
  • 38 Thigpen J T, Blessing J A, Ball H, Hummel S J, Barrett R J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.  J Clin Oncol. 1994;  12 1748-1753
    PubMedGoogle Scholar
  • 39 Sarosy G, Stone D A, Rothenberg M. et al . Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer.  J Clin Oncol. 1992;  10 1165-1170
    PubMedGoogle Scholar
  • 40 McGuire W P, Rowinsky E K, Rosenshein N B. et al . Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.  Ann Int Med. 1989;  111 273-279
    PubMedGoogle Scholar
  • 41 Gore M E, Levy V, Rustin G. et al . Paclitaxel (taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.  Br J Cancer. 1995;  72 1016-1019
    PubMedGoogle Scholar
  • 42 Sweeten K M, Gershenson D M, Burke T W, Morris M, Levenback C, Silva E G. Salvage chemotherapy for refractory transitional cell carcinoma of the ovary (TTC).   Gynecol Oncol. 1995;  59 211-215
    CrossrefPubMedGoogle Scholar
  • 43 Athanassiou A, Pectasides D, Varthalitis I, Dimitriades M, Tsiliakos S, Papazachariou A. Taxol patients with cis/carboplatin-refractory ovarian carcinoma.  Proc Am Soc Clin Oncol. 1994;  13 271
    PubMedGoogle Scholar
  • 44 ten Bokkel Huinink W, Gore M, Carmichael J. et al . Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.  J Clin Oncol. 1997;  15 2183-2193
    PubMedGoogle Scholar
  • 45 du Bois A, Lueck H J, Buser K. et al . Extended phase II study of paclitaxel as 3 hour infusion in patients with ovarian cancer previously treated with platinum.  Eur J Cancer. 1997;  33 379-384
    CrossrefPubMedGoogle Scholar
  • 46 Markman M, Rose P, Kennedy A. et al . A phase II study of 96 hour paclitaxel (P) as salvage therapy in ovarian carcinoma (OC).  Proc Am Soc Clin Oncol. 1996;  15 283
    PubMedGoogle Scholar
  • 47 Colombo N, Marzola M, Parma G. et al . Paclitaxel vs. CAP (cyclophosphamide; adriamycin, cisplatin) in recurrent platinum sensitive ovarian cancer: a randomized phase II study.   Proc Am Soc Clin Oncol. 1996;  15 279
    PubMedGoogle Scholar
  • 48 Mayerhofer K, Kucera E, Zeisler H, Speiser P, Reinthaller A, Sevelda P. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy.  Gynecol Oncol. 1996;  64 109-113
    PubMedGoogle Scholar
  • 49 Tresukol D, Kudelka A P, Gonzales de Leon C. et al . Paclitaxel retreatment in patients with platinum and paclitaxel resistant ovarian cancer.  Eur J Gynaec Oncol. 1996;  17 188-191
    PubMedGoogle Scholar
  • 50 Bruzzone M, Catsafados E, Miglietta L. et al . Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients.  Oncology. 1996;  53 349-353
    PubMedGoogle Scholar
  • 51 Andersson H, Horvath G, Mellqvist L, Westberg R. et al . Taxol given weekly in advanced previously treated ovarian carcinomas - a pilot study.  Int J Gynecol Cancer. 1997;  7 262-266
    CrossrefPubMedGoogle Scholar
  • 52 Fields A, Hochster H, Runowicz C. et al . SDZ PSC 833/paclitaxel in paclitaxel refractory ovarian carcinoma: a phase II trial with renewed responses.  Proc Am Soc Clin Oncol. 1997;  16 351A
    PubMedGoogle Scholar
  • 53 Soulie P, Trandafir L, Taama A. et al . Schedule-dependent paclitaxel tolerance/activity: data from a 7 day infusion phase I study with pharmacokinetics in paclitaxel refractory ovarian cancer.  Anti-Cancer Drugs. 1997;  8 763-766
    PubMedGoogle Scholar
  • 54 Kuehnle H, Lenaz L, Meerpohl H G. et al . Etoposide in cisplatin-refractory ovarian cancer.  Proc Am Soc Clin Oncol. 1988;  7 527
    PubMedGoogle Scholar
  • 55 Markman M, Hakes T, Reichman B. et al . Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer.  J Cancer Res Clin Oncol. 1992;  119 55-57
    CrossrefPubMedGoogle Scholar
  • 56 Hoskins P J, Swenerton K D. Oral etoposide is active against platinum-resistant epithelial ovarian cancer.  J Clin Oncol. 1994;  12 60-63
    PubMedGoogle Scholar
  • 57 Kavanagh J J, Tresukosol D, De Leon C G. et al . Phase II study of prolonged oral etoposide in refractory ovarian cancer.  Int J Gynecol Cancer. 1995;  5 351-354
    CrossrefPubMedGoogle Scholar
  • 58 de Wit R, van der Burg M EL, v. d. Gaast A, Logmans A, Stoter G, Verweij J. Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy.  Ann Oncol. 1994;  5 656-657
    PubMedGoogle Scholar
  • 59 Rose P G, Blessing J A, Mayer A R, Homesly H D. Prolonged oral etoposide as second line therapy for platinum resistant (platr) and platinum sensitive (plats) ovarian carcinoma: a Gynecologic Oncology Group study.  Proc Am Soc Clin Oncol. 1996;  15 282
    PubMedGoogle Scholar
  • 60 Naumann R W, Alvarez R D, Segars E T. et al . A phase II study of high-dose etoposide as a second-line therapy in patients with epithelial ovarian cancer.  Proc Am Soc Clin Oncol. 1997;  16 364A
    PubMedGoogle Scholar
  • 61 Kuhn W, Schmalfeldt B, Pache L. et al . Disease-adapted relapse therapy for ovarian cancer: results of a prospective study.  Int J Oncol. 1998;  13 57-63
    PubMedGoogle Scholar
  • 62 Armstrong D, Rowinsky E, Donehower R, Rosenshein N, Walczak J, McGuire W. A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer.  Proc Am Soc Clin Oncol. 1995;  14 275
    PubMedGoogle Scholar
  • 63 Rowinsky E K, Grochow L B, Hendricks C B. et al . Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.  J Clin Oncol. 1992;  10 647-656
    PubMedGoogle Scholar
  • 64 Kudelka A P, Tresukosal D, Edwards C L. et al . Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.  J Clin Oncol. 1996;  14 1552-1557
    PubMedGoogle Scholar
  • 65 Gordon A, Bookman M, Malmstrom H. et al . Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group trial.  Proc Am Soc Clin Oncol. 1996;  15 282
    PubMedGoogle Scholar
  • 66 Creemers G J, Bolis G, Gore M. et al . Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.  J Clin Oncol. 1996;  14 3056-3061
    PubMedGoogle Scholar
  • 67 Hochster H, Speyer J, Wadler S. et al . Phase II study of topotecan (TPT) 21-day infusion in platinum-treated ovarian cancer: a highly active regimen. (a NYGOG study).  Proc Am Soc Clin Oncol. 1996;  15 285
    PubMedGoogle Scholar
  • 68 Swisher E M, Mutch D G, Rader J S, Elbendary A, Herzog T J. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.  Gynecol Oncol. 1997;  66 349
    PubMedGoogle Scholar
  • 69 Hoskins P, Eisenhauer E, Beare S. et al . Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study.  J Clin Oncol. 1998;  16 2233-2237
    PubMedGoogle Scholar
  • 70 Bookman M A, Malmström H, Bolis G. et al . Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.  J Clin Oncol. 1998;  16 3345-3352
    PubMedGoogle Scholar
  • 71 National Institutes of Health Consensus Developement Conference Statement . Ovarian Cancer: screening, treatment, and follow-up.  Gynecol Oncol. 1994;  55 S4-S14
    CrossrefPubMedGoogle Scholar
  • 72 Schwartz P E, Keating G, Kohorn E I, Chambers J T. CHAP II therapy for epithelial ovarian cancers following primary treatment with platinum-based combination chemotherapy.   Gynecol Oncol. 1986;  25 340-346
    CrossrefPubMedGoogle Scholar
  • 73 Fanning J, Hilgers R D, Hutson E. Carboplatin, etoposide, and ifosfamide as second-line treatment for ovarian cancer.  Am J Clin Oncol. 1994;  17 335-337
    PubMedGoogle Scholar
  • 74 Lorusso V, Catino A, Leone B. et al . Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: a pilot study.  J Clin Oncol. 1993;  11 1952-1956
    PubMedGoogle Scholar
  • 75 Lele S B, Piver M S, Malfetano J. Cisplatin plus VP16-213 in refractory ovarian carcinoma.  Am J Clin Oncol. 1987;  10 21-22
    PubMedGoogle Scholar
  • 76 Baker T R, Piver M S, Hempling R E. The addition of etoposide and ifosfamide to cisplatin as second line therapy in ovarian carcinoma.  Eur J Gynaec Oncol. 1993;  14 18-22
    PubMedGoogle Scholar
  • 77 Menczer J, Ben-Baruch G, Rizel S, Brenner H. Cisplatin in combination with continuous VP16 infusion as second line chemotherapy in ovarian carcinoma.  Eur J Gynaec Oncol. 1992;  13 316-318
    PubMedGoogle Scholar
  • 78 Ahmed F Y, King D M, Nicol B. et al . Preliminary results of infusional chemotherapy (cisplatin, epirubicin and 5-fluorouracil, ECF) for refractory and relapsed epithelial ovarian cancer.  Proc Am Soc Clin Oncol. 1995;  14 280
    PubMedGoogle Scholar
  • 79 ten Bokkel Huinink W W, Dalesio O, Rodenhuis. Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at the Netherlands Cancer Institute.  Sem Oncol. 1992;  19 99-101
    PubMedGoogle Scholar
  • 80 Beddoe A M, Dottino P R, Cohen C J. Phase II trial of etoposide, carboplatin, and ifosfamide as salvage therapy in advanced ovarian carcinoma.  Mt Sinai J Med. 1993;  60 311-316
    PubMedGoogle Scholar
  • 81 Dobbs S P, Gribbin C, Chan S Y, Bessel E M. Second-line treatment with ifosfamide and carboplatin in patients with ovarian carcinoma relapsing after treatment with carboplatin.  Eur J Cancer. 1994;  30A 30-33
    PubMedGoogle Scholar
  • 82 De Lena M, Lorusso V, Bottalico C. Revertant and potentiating activity of lonidamin in patients with ovarian cancer previously treated with platinum.  J Clin Oncol. 1997;  15 3208-3213
    PubMedGoogle Scholar
  • 83 van der Burg M EL, Logmans A, de Wit R. et al . Six weeks of weekly high-dose cisplatin (P) and daily oral vepesid (VP): a highly active regimen for ovarian cancer patients (PTS) failing on or relapsing after conventional platinum containing combination chemotherapy.  Proc Am Soc Clin Oncol. 1996;  15 285
    PubMedGoogle Scholar
  • 84 Bower M, Goodchild K, Evans H, Nelstdorf A, Rustin G JS. FaFEC: a novel regimen for advanced ovarian cancer.  Int J Gynecol Cancer. 1997;  7 14-17
    PubMedGoogle Scholar
  • 85 Johnston C M, Pearl M L, Reynolds R K, Roberts J A, Morley G W. Treatment of refractory ovarian carcinoma with paclitaxel and cisplatin after treatment failure with single-agent paclitaxel.  Eur J Gynaec Oncol. 1995;  16 439-447
    PubMedGoogle Scholar
  • 86 Goldberg J M, Piver M S, Hempling R H, Recio F O. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer.  Gynecol Oncol. 1996;  63 312-317
    CrossrefPubMedGoogle Scholar
  • 87 Guastalla J P, Pujade-Lauraine E, Orfeuvre H. et al . Efficacy and safety of carboplatin (Cb)-paclitaxel (Px) association in pretreated advanced ovarian cancer (AOC) patients (pts).  Proc Am Soc Clin Oncol. 1996;  15 278
    PubMedGoogle Scholar
  • 88 Kosmas C, Polyzos A, Tsavaris N. et al . Outpatient, taxol (T) ifosfamide (I) and cisplatin (C) (TIP) as salvage chemotherapy in pretreated patients with ovarian cancer (O.C.).  Proc Am Soc Clin Oncol. 1998;  17 366A
    PubMedGoogle Scholar
  • 89 Guastalla J P, Pujade-Lauraine E, Weber B. et al . Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma.  Ann Oncol. 1998;  9 37-43
    CrossrefPubMedGoogle Scholar
  • 90 Sugiyama T, Yakushiji M, Nishida T. et al . Irinotecan (CPT-11) combined with cisplatin on patients with refractory or recurrent ovarian cancer.  Cancer Letters. 1998;  128 211-218
    CrossrefPubMedGoogle Scholar
  • 91 Baekelandt M, Covelli A, Trope C, Kristensen G. Phase I/II trial of cisplatin and doxorubicin with SDZ PSC 833 in patients with refractory ovarian cancer.  Proc Am Soc Clin Oncol. 1997;  16 757
    PubMedGoogle Scholar
  • 92 Bruckner H W, Cagnoni P J, Lee J M, Chesser M R, Andreotti P E. A sequence of adriamycin and taxol infusions for refractory ovarian cancer.  Proc Am Soc Clin Oncol. 1994;  13 271
    PubMedGoogle Scholar
  • 93 Behrens B, Copeland L, Balcerzak S, Staubus A, Vandre D, Villasmil P. A phase I taxol (T)/altretamine (A) doublet clinical trial in women with refractory ovarian cancer (OC). NCI #T92-0014.  Proc Am Soc Clin Oncol. 1994;  13 271
    PubMedGoogle Scholar
  • 94 Santoro A, Maiorino L, Santoro M. Taxol (T) plus doxorubicin (D) in platinum (P) pretreated advanced ovarian cancer (A.O.C.) patients (PTS).  Proc Am Soc Clin Oncol. 1996;  15 288
    PubMedGoogle Scholar
  • 95 Klaassen U, Harstrick A, Stahl M. et al . Paclitaxel and ifosfamide in pretreated patients with advanced ovarian carcinoma - results of a phase I/II study.  Proc Am Soc Clin Oncol. 1996;  15 295
    PubMedGoogle Scholar
  • 96 Dimopoulos M A, Papadimitriou C, Gennatas C. et al . Ifosfamide and paclitaxel salvage chemotherapie for advanced epithelial ovarian cancer.  Ann Oncol. 1997;  8 195-197
    CrossrefPubMedGoogle Scholar
  • 97 Kurbacher C M, Bruckner H W, Cree I A. et al . Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.  Clin Cancer Res. 1997;  3 1527-1533
    PubMedGoogle Scholar
  • 98 Trope C, Kaern J, Hogberg T. A phase II study of paclitaxel and doxorubicin as second-line treatment in recurrent ovarian cancer after cisplatin failure.  Gynecol Oncol. 1998;  68 123
    PubMedGoogle Scholar
  • 99 Kurtz J E, Deplanque G, Duclos B. et al . Paclitaxel-anthracycline combination chemotherapy in relapsing advanced ovarian cancer after platinum-based chemotherapy: a pilot study.  Gynecol Oncol. 1998;  70 414-417
    CrossrefPubMedGoogle Scholar
  • 100 Evans B D, Raju K S, Calvert A H, Harland S J, Wiltshaw E. Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma.  Cancer Treat Rep. 1983;  67 997-1000
    PubMedGoogle Scholar
  • 101 Bruckner H W, Wallach R, Cohen C J. et al . High-dose platinum for the treatment of refractory ovarian cancer.  Gynecol Oncol. 1981;  12 64-67
    CrossrefPubMedGoogle Scholar
  • 102 Ozols R F, Ostchega Y, Myers C E, Young R C. High-dose cisplatin in hypertonic saline in refractory ovarian cancer.  J Clin Oncol. 1985;  3 1246-1250
    PubMedGoogle Scholar
  • 103 Barker G H, Wiltshaw E. Use of high-dose cis-dichlorodiammine platinum (II) (NSC-119875) following failure on previous chemotherapy for advanced carcinoma of the ovary.  Br J Obstet Gynaecol. 1981;  88 1192-1199
    PubMedGoogle Scholar
  • 104 Markman M, Rothman R, Hakes T. et al . Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.  J Clin Oncol. 1991;  9 389-393
    PubMedGoogle Scholar
  • 105 Gore M E, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds.  Cynecol Oncol. 1990;  36 207-211
    PubMedGoogle Scholar
  • 106 Kehoe S, Redman C, Varma R. et al . Single agent high-dose cisplatin (200 mg/m2) treatment in ovarian carcinoma.  Br J Cancer. 1992;  66 717-719
    PubMedGoogle Scholar
  • 107 Reed E, Janik J, Bookman M A. et al . High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer.  J Clin Oncol. 1993;  11 2118-2126
    PubMedGoogle Scholar
  • 108 Bolis G, Brusati M, Ferraris A. et al . Carboplatin alone (C) vs. carboplatin + high-dose epirubicin (HDCE) + growth-factors (GF) in late recurrences ovarian cancer patients (PTS).  Proc Am Soc Clin Oncol. 1994;  13 271
    PubMedGoogle Scholar
  • 109 Conte P F, Gadducci A, Fioretti P, Bruzzone M, Brunetti I, Ragni N. Therapeutic experience of the North-West Oncology Group (GONO) on ovarian carcinoma.  Eur J Gynaec Oncol. 1994;  15 313-318
    PubMedGoogle Scholar
  • 110 Morgan R J, Margolin K, Raschko J. et al . Phase I trial of carboplatin and infusional cyclosporine in advanced malignancy.  J Clin Oncol. 1995;  13 2238-2246
    PubMedGoogle Scholar
  • 111 Bolis G, Scarfone G, Luchinin L. et al . Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with cisplatin- or carboplatin-based regimens.  Eur J Cancer. 1994;  30A 1764-1768
    PubMedGoogle Scholar
  • 112 Dorval T, Soussain C, Beuzeboc P. et al . Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer.  J Infus Chemother. 1996;  6 47-49
    PubMedGoogle Scholar
  • 113 Willemse P HB, Gietema J A, Mulder N H. et al . Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex.  Eur J Cancer. 1993;  29A 359-362
    PubMedGoogle Scholar
  • 114 Einzig A I, Wiernik P H, Sasloff J, Runowicz C D, Goldberg G L. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma.  J Clin Oncol. 1992;  10 1748-1753
    PubMedGoogle Scholar
  • 115 Kohn E C, Sarosy G, Bicher A. et al . Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer.  J Natl Cancer Inst. 1994;  86 18-24
    PubMedGoogle Scholar
  • 116 Chopra R, Ramesh N, Katiyar C K. A phase I-II study of intaxel, paclitaxel (PCL) obtained from himalayan yew tree (taxus baccata) in advanced ovarian cancer patients (PTS): an Indian experience.  Proc Am Soc Clin Oncol. 1995;  14 280
    PubMedGoogle Scholar
  • 117 Mendiola C, Garcia-Ribas I, Cubedo R. et al . High response rate of taxol in platinum pretreated advanced ovarian cancer.  Proc Am Soc Clin Oncol. 1995;  14 278
    PubMedGoogle Scholar
  • 118 Omura G A, Brady M F, Delmore J E. et al . A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study.  Proc Am Soc Clin Oncol. 1996;  15 280
    PubMedGoogle Scholar
  • 119 Abu-Rustum N R, Aghajanian C, Barakat R R, Fennelly D, Shapiro F, Spriggs D. Salvage weekly paclitaxel in recurrent ovarian cancer.  Sem Oncol. 1997;  24 S15-62-S15-67
    PubMedGoogle Scholar
  • 120 Fennelly D, Aghajanian C, Shapiro F. et al . Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.  J Clin Oncol. 1997;  15 187-192
    PubMedGoogle Scholar
  • 121 Ezcurdia L, Jovtis S L, Mickiewicz E. et al . Paclitaxel in platinum-resistant ovarian cancer patients.  Sem Oncol. 1997;  24 (suppl 15) S 15-53, S 15-56
    PubMedGoogle Scholar
  • 122 Markman M, Rose P G, Jones E. et al . Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens.  J Clin Oncol. 1998;  16 1849-1851
    PubMedGoogle Scholar
  • 123 Pectasides D, Papadopoulou M, Varthalitis J. et al . Paclitaxel in cisplatin or carboplatin-pretreated ovarian cancer.  Oncology. 1998;  55 228-234
    PubMedGoogle Scholar
  • 124 Eckhardt S, Hernadi Z, Thurzo L. et al . Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a second-line treatment in ovarian cancer.  Oncology. 1990;  47 289-295
    PubMedGoogle Scholar
  • 125 Hansen F, Malthe I, Krog H. Phase II clinical trial of VP-16-213 (etoposide) administered orally in advanced ovarian cancer.  Gynecol Oncol. 1990;  36 369-370
    CrossrefPubMedGoogle Scholar
  • 126 Hillcoat B L, Campbell J J, Pepperell R, Quinn M A, Bishop J F, Day A. Phase II trial of VP-16-213 in advanced ovarian carcinoma.  Gynecol Oncol. 1985;  22 162-166
    CrossrefPubMedGoogle Scholar
  • 127 Seymour M T, Mansi J L, Gallagher C J. et al . Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.  Br J Cancer. 1994;  69 191-195
    PubMedGoogle Scholar
  • 128 Marzola M, Zucchetti M, Colombo N. et al . Low-dose oral etoposide in epithelial cancer of the ovary.  Ann Oncol. 1993;  4 517-519
    PubMedGoogle Scholar
  • 129 Kühnle J, Hilfrich J. Chemotherapie des fortgeschrittenen Ovarialkarzinoms.  Onkologie. 1985;  8 374-382
    PubMedGoogle Scholar
  • 130 Yasumizu T, Kato J. Clinical trial of daily low-dose oral etoposide for patients with residual or recurrent cancer of the ovary or uterus.  J Obstet Gynaecol. 1995;  21 569-576
    PubMedGoogle Scholar
  • 131 de Jong R S, Hofstra L S, Willemse P HB. et al . Effect of low-dose oral etoposide on serum CA-125 in patients with advanced epithelial ovarian cancer.  Gynecol Oncol. 1997;  66 197-201
    CrossrefPubMedGoogle Scholar
  • 132 Garrow G C, Hainsworth J D, Johnson D H. et al . Prolonged administration of oral etoposide in previously-treated epithelial ovarian cancer: a phase II trial.  Proc Am Soc Clin Oncol. 1992;  11 236
    PubMedGoogle Scholar
  • 133 Gore M, Rustin G, Calvert H. et al . A multicentre, randomised, phase III study of topotecan (T) administered intravenously or orally for advanced epithelial ovarian carcinoma.  Proc Am Soc Clin Oncol. 1998;  17 349A
    PubMedGoogle Scholar
  • 134 Clarke-Pearson D L, Van Le L, Iveson T. et al . A phase II study of oral topotecan as a single agent, second-line therapy, administered for five days in patients with advanced ovarian cancer.  Proc Am Soc Clin Oncol. 1998;  17 363A
    PubMedGoogle Scholar
  • 135 Eisenhauer E, Hoskins P, Beare S. et al . Randomized phase II study of two schedules of topotecan in previously treated epithelial ovarian cancer (EOC).  Proc Am Soc Clin Oncol. 1997;  16 249A
    PubMedGoogle Scholar
  • 136 Dunton C J, Neufeld J, Carlson J A. et al . Secondary response of ovarian tumors to topotecan treatment.  Gynecol Oncol. 1998;  69 258-259
    CrossrefPubMedGoogle Scholar
  • 137 Ghosh K, Murray K P, Chen M D. et al . The role of extreme drug resistance assays on chemotherapeutic choice and response in ovarian carcinoma patients undergoing secondary cytoreductive surgery.  Gynecol Oncol. 1998;  70 310
    PubMedGoogle Scholar
  • 138 Veldhuis G J, Willemse P HB, Beijnen J H. et al . Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.  Br J Cancer. 1997;  75 703-709
    PubMedGoogle Scholar
  • 139 van der Burg M EL, de Wit R, Stoter G, Verweij J. Phase I study of weekly cisplatin (P) and weekly or 4-weekly taxol (T): a highly active regimen in advanced epithelial ovarian cancer (OC).  Proc Am Soc Clin Oncol. 1998;  17 335A
    PubMedGoogle Scholar
  • 140 Vincent P, Guastalla J P, Piedbois P. et al . Taxol (T) + carboplatin (Cb) combination in pretreated ovarian cancer (OC): a randomized comparison of 2 carboplatin dose calculations (AUC vs. BSA).  Proc Am Soc Clin Oncol. 1998;  17 1453
    PubMedGoogle Scholar
  • 141 Rose P G, Fusco N, Fluellen L, Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.  J Clin Oncol. 1998;  16 1494-1497
    PubMedGoogle Scholar
  • 142 Coeffic D, Benhammouda A, Antoine E C. et al . Phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma: preliminary results.  Sem Oncol. 1996;  23 5-8
    PubMedGoogle Scholar
  • 143 van der Burg M EL, Hoff A M, van Lent M, Rodenburg C J, van Putten W LJ, Stoter G. Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy.  Eur J Cancer. 1991;  27 248-250
    PubMedGoogle Scholar
  • 144 Dittrich C, Baur M, Vavra N. et al . Etoposide and carboplatin as salvage and first-line therapy in ovarian cancer patients.  Ann Oncol. 1993;  4 697-699
    PubMedGoogle Scholar
  • 145 Chambers S K, Chambers J T, Kohorn E I, Schwartz P E. et al . Etoposide (VP-16-213) plus cis-diamminedichloroplatinum as salvage therapy in advanced epithelial ovarian cancer.  Gynecol Oncol. 1987;  27 233-240
    CrossrefPubMedGoogle Scholar
  • 146 Dottino P R, Goodman H M, Kredentser D, Rosenberg M, Cohen C J. Clinical trial of etoposide and cisplatin as salvage therapy in advanced ovarian carcinoma.  Gynecol Oncol. 1987;  27 350-356
    CrossrefPubMedGoogle Scholar
  • 147 Seltzer V, Vogl S, Kaplan B. Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent.  Gynecol Oncol. 1985;  21 167-176
    CrossrefPubMedGoogle Scholar
  • 148 Metzner M, Logue J, Wilkinson P M, James R D. Treatment of relapsed ovarian carcinoma with epirubicin, cis-platinum and 5-fluorouracil (ECF).  Proc Am Soc Clin Oncol. 1995;  14 279
    PubMedGoogle Scholar
  • 149 Martoni A, Panetta A, Angelelli B, Melotti B, Pannuti F. A phase II study of carboplatin and cyclophosphamide in advanced ovarian carcinoma.  J Chemother. 1993;  5 47-51
    PubMedGoogle Scholar
  • 150 Gershenson D M, Kavanagh J J, Copeland L J, Stringer C A, Morris M, Wharton J T. Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy.  Obstet Gynecol. 1989;  73 798-802
    PubMedGoogle Scholar
  • 151 Chain J M, Collins C, Petrersdorf S. et al . Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer.  Am J Obstet Gynecol. 1996;  174 1688-1694
    PubMedGoogle Scholar
  • 152 Bruckner H W, Cohen C J, Bhardwaj S, Feuer E, Chesser M R, Holland J F. Schedule and dosage modification of a cyclophosphamide, hexamethylmelamine, doxorubicin, cisplatin combination chemotherapy regimen for refractory ovarian cancer.  Eur J Cancer Clin Oncol. 1989;  23 1273-1279
    PubMedGoogle Scholar
  • 153 Reed E, Sarosy G, Kohn E. et al . Phase I study of paclitaxel and cyclophosphamide in recurrent adenocarcinoma of the ovary.  Gynecol Oncol. 1996;  61 349-353
    CrossrefPubMedGoogle Scholar
  • 154 Olver I N, Davy M. A phase I study of paclitaxel and altretamine in ovarian cancer relapsing after cisplatin.  Proc Am Soc Clin Oncol. 1996;  15 297
    PubMedGoogle Scholar
  • 155 Pucci F, Bella M, Salvagni S, Passalacqua R, Attolini C, Cocconi G. Paclitaxel and ifosfamide in heavily pretreated patients with advanced ovarian cancer. A pilot fase II study.  Proc Am Soc Clin Oncol. 1996;  15 301
    PubMedGoogle Scholar
  • 156 Poole C J, Perren T, Hogberg T. et al . Phase I study to investigate the optimal dose and schedule of gemcitabine (G) and paclitaxel (P) in combination in patients with previously treated epithelial ovarian cancer.  Proc Am Soc Clin Oncol. 1998;  17 357A
    PubMedGoogle Scholar
  • 157 Olver I N, Davy M, Birgeois C. Paclitaxel and altretamine for ovarian cancer relapsing following cisplatin.  Proc Am Soc Clin Oncol. 1998;  17 317A
    PubMedGoogle Scholar
  • 158 Olver I, Davy M, Webster L, Egorin M, Luftner D, Park S H. A phase I trial with pharmacokinetics of paclitaxel and altretamine for ovarian cancer relapsing following cisplatin.  Ann Oncol. 1998;  9 68
    PubMedGoogle Scholar
  • 159 Belinson J L, Pretorius R G, McLure M, Ashikaga T. Hexamethylmelamine, methotrexate, 5-fluorouracil as second line chemotherapy after platinum for epithelial ovarian malignancies.  Gynecol Oncol. 1986;  23 304-309
    CrossrefPubMedGoogle Scholar
  • 160 Sipila P, Kivinen S, Gröhn P, Vesala J, Heinonen E. Phase II evaluation of peroral carmofur, cyclophosphamide, and hexamethylmelamine as a second-line therapy in advanced epithelial ovarian carcinoma.  Gynecol Oncol. 1989;  34 27-29
    CrossrefPubMedGoogle Scholar
  • 161 Trope C, Kaern J, Vergote I, Vossli S. A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas.  Cancer Chemother Pharmacol. 1990;  26 S45-S47
    CrossrefPubMedGoogle Scholar
  • 162 Bruzzone M, Campora E, Merlini L. et al . Ifosfamide and etoposide salvage treatment in advanced ovarian cancer.  J Chemother. 1991;  3 332-334
    PubMedGoogle Scholar
  • 163 Alberts D, Garcia-Kendall D, Surwit A. Phase II trial of mitomycin C plus 5-FU in the treatment of drug-refractory ovarian cancer.  Sem Oncol. 1988;  15 22-26
    PubMedGoogle Scholar
  • 164 Barlow J J, Lele S B. Etoposide (VP-16) plus cisplatin (DDP): a new active chemotherapeutic combination in patients with stage III-IV ovarian adenocarcinoma.  J Surg Oncol. 1986;  32 43-45
    PubMedGoogle Scholar
  • 165 Redman C, Lawton F, Stuart N. et al . Phase II study of combination 4'-epidoxorubicin and mitomycin C in recurrent epithelial ovarian cancer.  Cancer Chemother Pharmacol. 1989;  23 51-53
    PubMedGoogle Scholar
  • 166 Litam P P, Green J B, Capen C. Mitomycin-C-plus a 4 day continuous infusion of 5-fluorouracil as salvage regimen after platinum-based therapy in women with advanced ovarian cancer and related gynecologic malignancies.  Proc Am Soc Clin Oncol. 1996;  15 288
    PubMedGoogle Scholar
  • 167 Di Leo A, Bajetta E, Biganzoli L. et al . An I.T.M.O. Group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis.  Eur J Cancer. 1995;  31 2248-2254
    CrossrefPubMedGoogle Scholar
  • 168 Marzola M, Parma G, Bonazzi C. et al . Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer.  Ann Oncol. 1996;  7 419-421
    PubMedGoogle Scholar
  • 169 Nardi M, Della Giulia M, Pollera C F. et al . A combination of ifosfamide and mitoxantrone as salvage therapy in patients with advanced ovarian cancer.  Cancer Chemother Pharmacol. 1996;  38 298-301
    CrossrefPubMedGoogle Scholar
  • 170 Fleming G F, Waggoner S E, Rotmensch J, Skoog L A, Langhauser C. Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancer.  Gynecol Oncol. 1997;  65 42-45
    CrossrefPubMedGoogle Scholar
  • 171 Zanetta G, Lo Monico S, Gabriele A, Miceli D, Mangioni C. Chemotherapie with doxorubicin, etoposide and cyclophosphamide (DEC) in ovarian cancer persistent after platinum-based treatment.  Eur J Cancer. 1996;  32A 178-179
    PubMedGoogle Scholar
  • 172 Linasmita V, Wilailak S, Srispundit S, Tangtrakul S, Bullangpoti S, Israngura N. Ifosfamide/mesna plus adriamycin as salvage therapy of advanced epithelial ovarian cancer.  Int J Gynecol Cancer. 1997;  7 388-391
    CrossrefPubMedGoogle Scholar
  • 173 Herben V MM, ten Bokkel Huinink W W, Dubbelmann A C. et al . Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.  Br J Cancer. 1997;  76 1500-1508
    PubMedGoogle Scholar
  • 174 Guastalla J P, Ferrero J M, Benbunan J L. et al . Topotecan (T) followed by etoposide (E) in pretreated ovarian cancer (OC) patients (pts): a GINECO phase II study.  Ann Oncol. 1998;  9 67
    CrossrefPubMedGoogle Scholar
  • 175 Gwyther S J, Gore M E, ten Bokkel Huinink W. et al . Results of independent radiological review of over 400 patients with advanced ovarian cancer treated with topotecan (Hycamtin).  Proc Am Soc Clin Oncol. 1997;  16 1255
    PubMedGoogle Scholar
  • 176 Aghajanian C, Gogas H, Fennelly D. et al . Second-line paclitaxel therapy in patients with ovarian cancer previously treated with a taxane.  Proc Am Soc Clin Oncol. 1996;  15 69
    PubMedGoogle Scholar
  • 177 Schink J C, Narris L S, Grosen E A, Balley H H. Altretamine (hexalen) an effective salvage chemotherapy after paclitaxel (taxol) in women with recurrent platinum resistant ovarian cancer.  Proc Am Soc Clin Oncol. 1995;  14 275
    PubMedGoogle Scholar
  • 178 Markman M. Ifosfamide in the treatment of ovarian cancer.  Sem Oncol. 1996;  23 47-49
    PubMedGoogle Scholar
  • 179 Markman M, Kennedy A, Sutton G. et al . Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.  Gynecol Oncol. 1998;  70 272-274
    CrossrefPubMedGoogle Scholar
  • 180 Muggia F M, Hainsworth J D, Jeffers S. et al . Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.  J Clin Oncol. 1997;  15 987-993
    PubMedGoogle Scholar
  • 181 Shapiro J D, Millward M J, Rischin D. et al . Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel.  Gynecol Oncol. 1996;  63 89-93
    CrossrefPubMedGoogle Scholar
  • 182 Sugiyama T, Nishida T, Ookura N. et al . Is CPT-11 useful as a salvage chemotherapy for recurrent ovarian cancer?.  Proc Am Soc Clin Oncol. 1997;  16 378A
    PubMedGoogle Scholar
  • 183 de Palo G M, De Lena M, Di Re F, Luciani L, Valagussa P, Bonadonna G. Melphalan versus adriamycin in the treatment of advanced carcinoma of the ovary.  Surg Gynecol Obstet. 1975;  141 899-902
    PubMedGoogle Scholar
  • 184 Gordon A, Carmichael J, Malfetano J. et al . Final analysis of a phase III randomized study of Topotecan (T) vs paclitaxel (P) in advanced epithelial ovarian carcinoma (OC): International Topotecan Study Group.  Proc Am Soc Clin Oncol. 1998;  17 1374
    PubMedGoogle Scholar
  • 185 Neijt J P, ten Bokkel Huinink W W, van der Burg M EL. et al . Combination chemotherapy with or without hexamethylmelamine in alkylating-agent resistant ovarian carcinoma.  Cancer. 1984;  53 1467-1472
    PubMedGoogle Scholar
  • 186 Pater J L, Carmichael J A, Krepart G V. et al . Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin.  Cancer Treat Rep. 1987;  71 277-281
    PubMedGoogle Scholar
  • 187 Krafft W. Die Effektivität von Platin als Mono- und Kombinationstherapie bei primär resistentem oder rezidivierendem Ovarialkarzinom.  Zentralbl Gynäkol. 1989;  14 938-946
    PubMedGoogle Scholar
  • 188 Park R C, Blom J, Disaia P J, Lagasse L D, Blessing J A. Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5-fluorouracil and dactinomycin or with combination of cytoxan, 5-fluorouracil and dactinomycin.  Cancer. 1980;  45 2529-2542
    PubMedGoogle Scholar
  • 189 Eisenhauer E A, Vermorken J B, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients.  Ann Oncol. 1997;  8 963-968
    CrossrefPubMedGoogle Scholar
  • 190 Hoskins P, Tu D, James K, Koski B. Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: A prediction tree analysis-derived model with test and validation groups.  Gynecol Oncol. 1998;  70 224-230
    CrossrefPubMedGoogle Scholar
  • 191 Williams C J. Tamoxifen in relapsed ovarian cancer: A systematic review.  Int J Gynecol Cancer. 1998;  8 89-94
    CrossrefPubMedGoogle Scholar
  • 192 Kavanagh J J, Roberts W, Townsend P, Hewitt S. Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer.  J Clin Oncol. 1989;  7 115-118
    PubMedGoogle Scholar
  • 193 Miller D S, Brady M F, Barrett R J. A phase II Trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group study.  Am J Clin Oncol. 1992;  15 125-128
    PubMedGoogle Scholar
  • 194 Bruckner H W, Motwani B T. Treatment of advanced refractory ovarian carcinoma with a gonadotropin-releasing hormone analogue.  Am J Obstet Gynecol. 1989;  161 1216-1218
    PubMedGoogle Scholar
  • 195 Kurbacher C M, Bruckner H W, Mallmann P, Krebs D. Mitoxantron kombiniert mit Paclitaxel beim platinrefraktären Ovarialkarzinomrezidiv: Präklinische und erste klinische Resultate.  Arch Gynecol Obstet. 1996;  258 S19
    PubMedGoogle Scholar
  • 196 Eltabbakh G H, Piver M S, Hempling R E. et al . Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.  Gynecol Oncol. 1998;  70 392-397
    CrossrefPubMedGoogle Scholar
  • 197 Morgan R J, Speyer J, Doroshow J H. et al . Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels.  Gynecol Oncol. 1995;  58 79-85
    CrossrefPubMedGoogle Scholar
  • 198 Long III H J, Nelimark R A, Su J Q. et al . Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma.  Gynecol Oncol. 1994;  54 180-183
    CrossrefPubMedGoogle Scholar
  • 199 de Graeff A, van Hoef M EHM, Tjia P, Heintz A PM, Neijt J P. Continuous infusion of 5-fluorouracil in ovarian cancer patients refractory to cisplatin and carboplatin.  Ann Oncol. 1991;  2 691-692
    PubMedGoogle Scholar
  • 200 van Oosterom A T, ten Bokkel Huinink W, van der Burg M EL, Vermorken J B, Willemse P HB, Neijt J P. Phase II clinical trial of doxyfluridine in patients with advanced ovarian cancer.  Eur J Cancer. 1991;  27 747-749
    PubMedGoogle Scholar
  • 201 Louvet C, de Gramont A, Demuynck B. et al . Bi-weekly 2-day schedule of high-dose folinic acid, 5-fluorouracil bolus and infusion in pretreated advanced epithelial ovarian cancer: a phase II study.  Ann Oncol. 1992;  3 657-658
    PubMedGoogle Scholar
  • 202 Reed E, Jacob J, Ozols R F, Young R C, Allegra C. 5-fluorouracil (5-FU) and leucovorin in platinum-refractory advanced stage ovarian carcinoma.  Gynecol Oncol. 1992;  46 326-329
    CrossrefPubMedGoogle Scholar
  • 203 Look K Y, Muss H B, Blessing J A, Morris M. A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma.  Clin Oncol. 1995;  18 19-22
    PubMedGoogle Scholar
  • 204 Kamphuis J T, Huider M C, Ras G J. et al . High-dose 5-fluorouracil and leucovorin as second-line chemotherapy in patients with platinum-resistant epithelial ovarian cancer.  Cancer Chemother Pharmacol. 1995;  37 190-192
    PubMedGoogle Scholar
  • 205 Sorensen P, Pfeiffer P, Bertelsen K. A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy.  Gynecol Oncol. 1995;  56 75-78
    CrossrefPubMedGoogle Scholar
  • 206 Markman M, Hakes T, Reichman B. et al . Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.  J Clin Oncol. 1992;  10 243-248
    PubMedGoogle Scholar
  • 207 Gropp M, Meier W, Hepp H. Treosulfan als effiziente Second-line-Therapie beim Ovarialkarzinom.  Geburtsh u Frauenheilk. 1997;  57 356-360
    PubMedGoogle Scholar
  • 208 Harstrick A, Wilke H, Eberhard W. et al . A phase I dose escalation trial of intravenous treosulfan in refractory cancer.  Onkologie. 1996;  19 153-156
    PubMedGoogle Scholar
  • 209 Keldsen N, Madsen E L, Havsteen H. et al . Oral treosulfan as second-line treatment in platinum-resistant ovarian cancer: a phase II study.  Gynecol Oncol. 1998;  69 100-102
    CrossrefPubMedGoogle Scholar
  • 210 Hauge M D, Long H J, Hartmann L C, Edmonson J H, Webb M J, Su J. Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer.  Invest New Drugs. 1992;  10 299-301
    CrossrefPubMedGoogle Scholar
  • 211 Vergote I, Himmelmann A, Frankendal B, Scheistroen M, Vlachos K, Trope C. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer.  Gynecol Oncol. 1992;  47 282-286
    CrossrefPubMedGoogle Scholar
  • 212 Moore D H, Valea F, Crumpler L S, Fowler W C. Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma.  Gynecol Oncol. 1993;  51 109-112
    CrossrefPubMedGoogle Scholar
  • 213 Vermorken J B, Kobierska A, van der Burg M EL. et al . High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: the EORTC-GCCG experience.  Eur J Gynaec Oncol. 1995;  16 433-438
    PubMedGoogle Scholar
  • 214 Gaducci A, Brunetti I, Muttini M P. et al . Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer.  Eur J Cancer. 1994;  30A 1432-1435
    PubMedGoogle Scholar
  • 215 Havsteen H, Bertelsen K, Gadeberg C C. et al . A phase 2 study with epirubicin as second-line treatment of patients with advanced epithelial ovarian cancer.  Gynecol Oncol. 1996;  63 210-215
    CrossrefPubMedGoogle Scholar
  • 216 Safra T, Jeffers S, Groshen S. et al . Doxil (D) in platinum-refractory epithelial ovarian cancer (EOC): results from three consecutive phase I/II studies.  Proc Am Soc Clin Oncol. 1997;  16 349A
    PubMedGoogle Scholar
  • 217 Garcia A, Muggia F M. Activity of anthracyclines in refractory ovarian cancer: recent experience and review.  Cancer Invest. 1997;  15 329-334
    PubMedGoogle Scholar
  • 218 Pelaez I, Lacave A J, Palacio I. et al . Phase II trial of epirubicin at standard dose in relapsed ovarian cancer.  Eur J Cancer. 1996;  32A 899-900
    PubMedGoogle Scholar
  • 219 Locatelli M C, D'Antona A, Vinci M, Carcione R, Pasquinucci C, Luporini G. Trattamento di 2° linea del carcinoma ovarico avanzato (CAO) con epirubicina (EDR).  Tumori. 1997;  76 138
    PubMedGoogle Scholar
  • 220 Lund B, Hansen O P, Theilade K, Hansen M, Neijt J P. Phase II study of gemcitabine (2'.2'-difluorodeoxycytidine) in previously treated ovarian cancer patients.  J Natl Cancer Inst. 1994;  86 1530-1533
    PubMedGoogle Scholar
  • 221 Neijt J P, Kaufmann M, Bauknecht T. et al . Gemcitabine in pretreated ovarian cancer.  Ann Oncol. 1996;  7 70
    PubMedGoogle Scholar
  • 222 George M J, Heron J F, Kerbrat P. et al . Navelbine in advanced ovarian epithelial cancer: a study of the French Oncology Centers.  Sem Oncol. 1989;  16 30-32
    PubMedGoogle Scholar
  • 223 Bajetta E, Di Leo A, Biganzoli L. et al . Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease.  J Clin Oncol. 1996;  14 2546-2551
    PubMedGoogle Scholar
  • 224 Gershenson D M, Burke T W, Morris M. et al . A phase I study of a daily ×3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.  Gynecol Oncol. 1998;  70 404-409
    CrossrefPubMedGoogle Scholar
  • 225 Vergote I B, Trope C G. Ifosfamide-etoposide therapy in platin-resistant ovarian carcinoma.  Proc Am Soc Clin Oncol. 1995;  14 273
    PubMedGoogle Scholar
  • 226 Look K Y, Blessing J A, Muss H B, DeGeest K. 5-fluorouracil and low-dose leucovorin in the treatment of recurrent epithelial ovarian carcinoma.  Am J Clin Oncol. 1992;  15 494-496
    PubMedGoogle Scholar
  • 227 Burnett A F, Barter J F, Potkul R K, Barnes W A. Ineffectiveness of continuous 5-fluorouracil as salvage therapy for ovarian cancer.  Am J Clin Oncol. 1994;  17 490-493
    PubMedGoogle Scholar
  • 228 Prefontaine M, Donovan J T, Powell J L, Buley L. Treatment of refractory ovarian cancer with 5-fluorouracil and leucovorin.  Gynecol Oncol. 1996;  61 249-252
    CrossrefPubMedGoogle Scholar
  • 229 Hoffmann L, Koppermann S, Müllerleile U. Treosulfan in the treatment of ovarian carcinoma.  Onkologie. 1991;  14 8-9
    PubMedGoogle Scholar
  • 230 Kramer D, Golz N, Glaser D, Mast H. Treosulfan als Second-Line-Therapie beim fortgeschrittenen Ovarialkarzinom.  Arch Gynecol Obstet. 1991;  250 195-196
    PubMedGoogle Scholar
  • 231 Friedlander M, De Gramont A, Millward M J. et al . Activity of gemcitabine in stage 3 or 4 ovarian cancer: patients previously treated with cisplatin (CP)-containing regimens.  Eur J Cancer. 1997;  33 S121-S122
    PubMedGoogle Scholar
  • 232 Coleman R, Towlson K, Wiltshaw E. et al . Epirubicin for pretreated advanced ovarian cancer.  Eur J Cancer. 1990;  26 850-851
    PubMedGoogle Scholar
  • 233 Ozols R F, Cunnion R E, Klecker R W. et al . Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.  J Clin Oncol. 1987;  5 641-647
    PubMedGoogle Scholar
  • 234 Gordon A N, Hainsworth J, Moore M. et al . Doxil (doxorubicin HCl liposome injection) in the treatment of patients with refractory advanced ovarian carcinoma - results of an interim analysis.  Proc Am Soc Clin Oncol. 1998;  17 1345
    PubMedGoogle Scholar
  • 235 Willemse P HB, van der Burg M EL, van der Gaast A. et al . Ifosfamide given as 24-h infusion with mesna in patients with recurrent ovarian cancer: preliminary results.  Cancer Chemother Pharmacol. 1990;  26 51-54
    CrossrefPubMedGoogle Scholar
  • 236 Sutton G P, Blessing J A, Homesley H D, Berman M L, Malfetano J. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group study.  J Clin Oncol. 1989;  7 1672-1676
    PubMedGoogle Scholar
  • 237 Rosen G F, Lurain J R, Newton M. Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy.  Gynecol Oncol. 1987;  27 173-179
    CrossrefPubMedGoogle Scholar
  • 238 Stehman F B, Ehrlich C E, Callangan M F. Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy.  Gynecol Oncol. 1984;  17 189-195
    CrossrefPubMedGoogle Scholar
  • 239 Maneta A, Tewari K, Podczaski E S. Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature.  Gynecol Oncol. 1997;  66 20-26
    CrossrefPubMedGoogle Scholar
  • 240 Moore D H, Fowler Jr W C, Jones C P, Crumpler L S. Hexamethylmelamine chemotherapy for persistent or recurrent epithelial ovarian cancer.  Am J Obstet Gynecol. 1991;  165 573-576
    PubMedGoogle Scholar
  • 241 Rustin G JS, Nelstorp A E, Crawford M. et al . Phase II trial of oral altretamine for relapsed ovarian carcinoma: evolution of defining response by serum CA 125.  J Clin Oncol. 1997;  15 172-176
    PubMedGoogle Scholar
  • 242 Burger R A, Burman S, White R, DiSaia P J. Phase II trial of navelbine in advanced epithelial ovarian cancer.  Proc Am Soc Clin Oncol. 1996;  15 286
    PubMedGoogle Scholar
  • 243 Rothenberg M L, Ostchega Y, Steinberg S M. et al . High-dose carboplatin with diethyldithiocarbamate chemoprotection in treatment of women with relapsed ovarian cancer.  J Natl Cancer Inst. 1988;  80 1488-1492
    PubMedGoogle Scholar

PD Dr. med. Andreas du Bois

Klinik für Gynäkologie und gynäkologische Onkologie

Dr.-Horst-Schmidt-Kliniken

Ludwig-Erhard-Straße 100

65199 Wiesbaden

Phone: Tel. 06 11/43 32 03

Fax: Fax 06 11/43 32 05

Email: E-mail: dubois.hsk-wiesbaden@uumail.de

      >